Vividion Initiates Phase I Trial for Oral STAT3 Inhibitor in Advanced Tumors

Vividion Therapeutics, a subsidiary of Bayer AG, has commenced a Phase I clinical trial for VVD-130850, an oral STAT3 inhibitor intended to treat advanced solid and hematologic tumors, both as a standalone treatment and in combination with checkpoint inhibitors. The compound is unique in that it modulates STAT3 function and the expression of its target genes without altering the protein's levels. This development is a significant achievement for Vividion's chemoproteomics platform, which is focused on identifying and developing therapies for traditionally undruggable targets in cancer and immune disorders.
The trial will assess the safety, tolerability, and preliminary efficacy of VVD-130850, as well as its pharmacokinetic and pharmacodynamic properties. The drug is designed to bind to a novel allosteric site on STAT3, inhibiting its DNA binding and downstream gene expression, which are implicated in cancer cell survival and growth. The STAT3 protein is a critical regulatory factor that, when hyperactivated, can contribute to tumor progression and resistance to treatment.
Vividion's chemoproteomics platform has been instrumental in advancing a pipeline of selective small molecule therapeutics aimed at high-value targets in oncology and immunology. The company's innovative approach has led to the discovery of numerous previously unknown functional sites on well-studied proteins associated with a range of diseases. Vividion's acquisition by Bayer in August 2021 has allowed it to maintain its entrepreneurial spirit while benefiting from Bayer's expertise in drug development and global resources.
Bayer is a global life sciences company with a focus on healthcare and nutrition, dedicated to sustainable development and positive societal impact. In fiscal 2022, the company had sales of €50.7 billion and employed approximately 101,000 people worldwide. The company's commitment to innovation and growth is evident in its R&D investments, which amounted to €6.2 billion before special items.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!